Integrated Quantitative Investments’s BioCryst Pharmaceuticals BCRX Stock Holding History

Integrated Quantitative Investments’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-65,365	Closed	-$622K	–	399
2026 Q1	$622K	Buy	+65,365	New	+$508K	0.11%	255

Other funds holding BCRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Jupiter Topco New York $245B AUM

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Integrated Quantitative Investments's BCRX Position: Q2 2026 in Review

Integrated Quantitative Investments sold out of BioCryst Pharmaceuticals (BCRX) in Q2 2026, closing a stake of 65,365 shares — an estimated $622K sold.

Integrated Quantitative Investments first reported a position in BCRX in Q1 2026 and held it in 1 quarter. The position peaked at $622K in Q1 2026. 318 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

Integrated Quantitative Investments reported no remaining BioCryst Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Integrated Quantitative Investments sold 65,365 BioCryst Pharmaceuticals shares in Q2 2026, an estimated $622K.
Integrated Quantitative Investments first reported a position in BioCryst Pharmaceuticals in Q1 2026 and held it in 1 quarter.
Integrated Quantitative Investments's BioCryst Pharmaceuticals position peaked at $622K in Q1 2026.
318 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on Integrated Quantitative Investments's 13F filing for Q2 2026, filed 14 Aug 2026.